Company: INKT
Filing Date: 2025-04-30
Form Type: DEF 14A
Source: 0000950170-25-061041
Chunk: 31

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-04-30
Form: DEF 14A
Chunk 31
---
     |               |   4,174 |     |      | 1,228 |
| Peter Behner      |     |               |   7,923 |     |      | 2,098 |
| Barbara Ryan      |     |               |  10,423 |     |      | 2,422 |

(3) Dr. Kadlec joined the Board effective October 30, 2024. In respect of their service on the Board in fiscal year 2024, each of our non-employee directors, other than Dr. Armen, was entitled to receive a $50,000 cash retainer and each member of a committee was entitled to receive the following cash fee, prorated for partial years of service:

| Additional annual cash retainer for Audit Committee Chair               |     | $ | 15,000 |
| Additional annual cash retainer for Audit Committee member              |     | $ |  7,500 |
| Additional annual cash retainer for Compensation Committee Chair        |     | $ | 10,000 |
| Additional annual cash retainer for Compensation Committee member       |     | $ |  6,000 |
| Additional annual cash retainer for Corporate Governance and Nominating 
 Committee Chair                                                         |     | $ |  7,500 |
| Additional annual cash retainer for Corporate Governance and Nominating 
 Committee member                                                        |     | $ |  4,000 |

On October 30, 2024, Dr. Kadlec was granted an option to purchase 4,174 shares of our common stock, which vests as to one-third (1/3) of the underlying shares on each of October 30, 2025, October 30, 2026, and October 30, 2027, generally subject to Dr. Kadlec’s continued service through the applicable vesting date.

<div align='center'>22</div>

OWNERSHIP OF OUR COMMON STOCK Ownership By Management On April 24, 2025, MiNK had 3,966,392 shares of common stock issued and outstanding. The table below shows certain information about the beneficial ownership of MiNK common stock, as of April 24, 2025, by: • each of our directors, • each of our named executive officers, and • all of our directors and executive officers as a group. In accordance with SEC rules, we have included in the column “Number of Issued Shares” all shares of common stock over which the person has